Full metadata record
|dc.contributor||Department of Optometry and Radiography||en_US|
|dc.publisher||Hong Kong Polytechnic University||-|
|dc.rights||All rights reserved||en_US|
|dc.title||Immunotherapeutic effect of an interleukin-2 immunoconjugate in animal model||en_US|
|dcterms.abstract||Recombinant antibody-cytokine fusion proteins are immunocytokines that deliver high cytokine concentrations in the targeted tumor microenvironment and thereby effectively stimulate cellular immune responses against human malignancies. Protoon-cogene HER-2/neu is overexpressed in some human breast, ovarian, prostate and lung cancers and associated with poor prognosis. A novel immunocytokine consisting of a recombinant human interleukin-2 (rhIL-2) and a recombinant humanized single chain antibody that combined the VH and VL portions of a murine monoclonal antibody (520C9) specific for human HER-2/neu positive tumors has been developed. The fusion protein H520C9sFv-rhIL-2 in combination with human peripheral blood mononuclear cells effectively inhibited growth and dissemination of subcutaneous xenograft and lung metastases of human HER-2/neu positive ovarian carcinoma in severe combined immunodeficient mice. In addition, histological staining and immunohistochemical analysis of lung metastases in the treatment group of SCID mice with the H520C9sFv-rhIL-2 and human PBM cells demonstrated significant suppression of metastatic tumor growth. A dose dependent response was also demonstrated by the effective inhibition of lung metastases at a dose level of 6 ug H520C9sFv-rhJL-2 instead of 3 ug H520C9sFv-rhIL-2 per injection with 2 x 105 human PBM cells. Such results demonstrated that immunocytokine-directed inter1eukin-2 therapy to tumors sites could be effective in an adjuvant setting for patients with disseminated metastases of human HER-2/neu positive tumors.||en_US|
|dcterms.extent||xiv, 87 leaves : ill. ; 30 cm||en_US|
|dcterms.isPartOf||PolyU Electronic Theses||en_US|
|dcterms.LCSH||Hong Kong Polytechnic University -- Dissertations||en_US|
|dcterms.LCSH||Interleukin 2 -- Therapeutic use||en_US|
Files in This Item:
|b17330932.pdf||For All Users||11.03 MB||Adobe PDF||View/Open|
As a bona fide Library user, I declare that:
- I will abide by the rules and legal ordinances governing copyright regarding the use of the Database.
- I will use the Database for the purpose of my research or private study only and not for circulation or further reproduction or any other purpose.
- I agree to indemnify and hold the University harmless from and against any loss, damage, cost, liability or expenses arising from copyright infringement or unauthorized usage.
By downloading any item(s) listed above, you acknowledge that you have read and understood the copyright undertaking as stated above, and agree to be bound by all of its terms.
Please use this identifier to cite or link to this item: